A link between autophagy and the pathophysiology of LRRK2 in Parkinson's disease

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Gómez Suaga, Patricia ^a   Fdez, Elena ^a   Blanca Ramírez, Marian ^a   Hilfiker, Sabine ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; GLYCINE; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 1; LEUCINE RICH REPEAT KINASE 2; NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; SERINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AUTOPHAGOSOME; AUTOPHAGY; BRAIN; CALCIUM SIGNALING; CELL DEATH; CELLULAR DISTRIBUTION; ENDOCYTOSIS; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LYSOSOME; MACROAUTOPHAGY; MEDIATOR; MISSENSE MUTATION; MUTANT; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; RNA INTERFERENCE; TISSUE SPECIFICITY;

EID: 84871838978     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/324521     Document Type: Review

References (22)

1. Halliday G., Lees A., Stern M., Milestones in Parkinson's disease-Clinical and pathologic features. Movement Disorders 2011 26 6 1015 1021 2-s2.0-79957586330 10.1002/mds.23669
2. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R. J., Calne D. B., Stoessl A. J., Pfeiffer R. F., Patenge N., Carbajal I. C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D. W., Meitinger T., Strom T. M., Wszolek Z. K., Gasser T., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004 44 4 601 607 2-s2.0-8844233579 10.1016/j.neuron.2004.11.005 (Pubitemid 39531225)
3. Paisán-Ruíz C., Jain S., Evans E. W., Gilks W. P., Simón J., Van Der Brug M., De Munain A. L., Aparicio S., Gil A. M., Khan N., Johnson J., Martinez J. R., Nicholl D., Carrera I. M., Peňa A. S., De Silva R., Lees A., Martí-Massó J. F., Pérez-Tur J., Wood N. W., Singleton A. B., Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004 44 4 595 600 2-s2.0-8844266996 10.1016/j.neuron.2004.10.023 (Pubitemid 39531224)
4. Farrer M. J., Genetics of Parkinson disease: paradigm shifts and future prospects. Nature Reviews Genetics 2006 7 4 306 318 2-s2.0-33645116252 10.1038/nrg1831
5. Hardy J., Genetic analysis of pathways to parkinson disease. Neuron 2010 68 2 201 206 2-s2.0-77957905690 10.1016/j.neuron.2010.10.014
6. Haugarvoll K., Wszolek Z. K., Clinical features of LRRK2 parkinsonism. Parkinsonism and Related Disorders 2009 15 3 S205 S208 2-s2.0-71849086433 10.1016/S1353-8020(09)70815-6
7. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., Tomiyama H., Nakashima K., Hasegawa K., Obata F., Yoshikawa T., Kawakami H., Sakoda S., Yamamoto M., Hattori N., Murata M., Nakamura Y., Toda T., Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics 2009 41 12 1303 1307 2-s2.0-70549084415 10.1038/ng.485
8. Simón-Sánchez J., Schulte C., Bras J. M., Sharma M., Gibbs J. R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S. W., Hernandez D. G., Krüger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M. A., Illig T., Gieger C., Houlden H., Steffens M., Okun M. S., Racette B. A., Cookson M. R., Foote K. D., Fernandez H. H., Traynor B. J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., Van Der Brug M., Lopez G., Chanock S. J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N. W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J. A., Singleton A. B., Gasser T., Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics 2009 41 12 1308 1312 2-s2.0-70549088602 10.1038/ng.487
9. Nalls M. A., Plagnol V., Hernandez D. G., Sharma M., Sheerin U. M., Saad M., Simón-Sánchez J., Schulte C., Lesage S., Sveinbjö rnsdóttir S., Stefánsson K., Martinez M., Hardy J., Heutink P., Brice A., Gasser T., Singleton A. B., Wood N. W., Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet 2011 377 9766 641 649 2-s2.0-79951811351 10.1016/S0140-6736(10)62345-8
10. Cookson M. R., Dauer W., Dawson T., Fon E. A., Guo M., Shen J., The roles of kinases in familial Parkinson's disease. Journal of Neuroscience 2007 27 44 11865 11868 2-s2.0-35948952469 10.1523/JNEUROSCI.3695-07.2007 (Pubitemid 350072099)
11. Rudenko I. N., Chia R., Cookson M. R., Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Medicine 2012 10, article 20
12. Bosgraaf L., Van Haastert P. J. M., Roc, a Ras/GTPase domain in complex proteins. Biochimica et Biophysica Acta 2003 1643 1-3 5 10 2-s2.0-0345118282 10.1016/j.bbamcr.2003.08.008 (Pubitemid 37494887)
13. Biskup S., West A. B., Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochimica et Biophysica Acta 2009 1792 7 625 633 2-s2.0-68949125734 10.1016/j.bbadis.2008.09.015
14. Greggio E., Cookson M. R., Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009 1 1 2-s2.0-77953395313 10.1042/AN20090007 e00002
15. Rudenko I. N., Kaganovich A., Hauser D. N., The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochemical Journal 2012 446 1 99 111
16. Guo L., Gandhi P. N., Wang W., Petersen R. B., Wilson-Delfosse A. L., Chen S. G., The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Experimental Cell Research 2007 313 16 3658 3670 2-s2.0-34548604567 10.1016/j.yexcr.2007.07.007 (Pubitemid 47404550)
17. Lewis P. A., Greggio E., Beilina A., Jain S., Baker A., Cookson M. R., The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochemical and Biophysical Research Communications 2007 357 3 668 671 2-s2.0-34247468302 10.1016/j.bbrc.2007.04.006 (Pubitemid 46653831)
18. Berwick D. C., Harvey K., LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends in Cell Biology 2011 21 5 257 265 2-s2.0-79955548865 10.1016/j.tcb.2011.01.001
19. Lewis P. A., Manzoni C., LRRK2 and human disease: a complicated question or a question of complexes? Science Signaling 2012 5 207, article 2
20. Greggio E., Zambrano I., Kaganovich A., Beilina A., Taymans J. M., Daniëls V., Lewis P., Jain S., Ding J., Syed A., Thomas K. J., Baekelandt V., Cookson M. R., The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. Journal of Biological Chemistry 2008 283 24 16906 16914 2-s2.0-47749114984 10.1074/jbc.M708718200
21. Deng J., Lewis P. A., Greggio E., Sluch E., Beilina A., Cookson M. R., Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proceedings of the National Academy of Sciences of the United States of America 2008 105 5 1499 1504 2-s2.0-40349101849 10.1073/pnas.0709098105 (Pubitemid 351346543)
22. Sen S., Webber P. J., West A. B., Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. Journal of Biological Chemistry 2009 284 52 36346 36356 2-s2.0-73649120624 10.1074/jbc.M109.025437